Why the study?
What are the clinical features, risk factors, and management strategies for neuroleptic malignant syndrome?
What are the clinical features, risk factors, and management strategies for neuroleptic malignant syndrome?
NMS is a rare but potentially lethal complication of neuroleptic therapy that requires prompt recognition and management.
Answers are grounded in this paper and cite their sources.
Demands sustained vigilance for NMS with neuroleptic use; leaves open refinement of risk prediction and prevention strategies.
Although a rare form of ‘lethal’ catatonia, involving high temperature and rigidity, was first described long before the advent of neuroleptic drugs, Delay's description of a syndrome malin in 1960 is usually regarded as the first recognition of this syndrome. Over the next 20 years the number of case reports grew and the appearance of reviews such as Caroff's in 1980 marked the birth of the neuroleptic malignant syndrome (NMS). Reports of its incidence give variation rates of up to fiftyfold, possibly due to differences in diagnostic criteria, and mortality reports are similarly variable. Although it is debatable whether it is a rare, severe idiosyncrasy or one of many neuromuscular side-effects of dopamine antagonists (Levinson & Simpson, 1986), most clinicians nowadays regard it as a serious but recognisable risk of neuroleptic treatment which merits further attention.
No takes yet. Share an insight, caveat, or question.
Kohen et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: